Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.
Completed
Norgine
Phase 1
2009-02-01
This is a healthy volunteer three-way crossover study. A total of 12 subjects will receive
three single administrations of 1 g rectal suppositories (containing either 5 mg NRL001, 10
mg NRL001 or matching placebo), with a washout period of at least 7 days between dosings. A
further 12 subjects will receive three single administrations of 2 g rectal suppositories
(containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), again with a 7 day washout
period between dosings. The pharmacodynamic response, pharmacokinetics and safety profile
will be determined.
Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum
Completed
Norgine
Phase 1
2007-04-01
Study to assess the effects of 10mg NRL001 on mean anal resting pressure (MARP) when
administered as a slow release suppository applied to the anal canal or rectum. In addition,
the pharmacokinetics of NRL001 in plasma, adverse events, and any changes in heart rate or
blood pressure were to be assessed.
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
Recruiting
Shanghai Zhongshan Hospital
Phase 4
2020-03-01
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective
well-accepted intervention strategy. Here we tried to classify TAK patients in 3 levels,
including mild, moderate, and severe, and prescribe methotrexate and tofacitinib randomly in
mild and moderate patients, to observe the relatively better treatment strategy, facilitating
better intervention strategy in TAK patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
